Group 1 - The China-Italy Eye Health Innovation Cooperation event was held in Beijing, focusing on practical cooperation in the eye health sector between China and Italy [1] - He Eye Hospital, a technology-driven listed company, aims to create a comprehensive ecosystem for eye health through its "Smart Light City" strategy, integrating AI, genetic technology, and regenerative medicine [1] - The collaboration emphasizes research and product development in key areas such as refractive cataracts, myopia prevention in youth, and dry eye treatment, aiming to provide Chinese patients with access to top global eye health products and services [1] Group 2 - He Eye Hospital has been dedicated to the eye health field for 30 years, combining technological innovation with public welfare services to create a new ecosystem for eye health [2] - The "three-tier eye health medical service model" developed by He Eye Hospital has gained industry recognition as a replicable and sustainable public health model [2] - The successful event marks an important step for He Eye Hospital in promoting international cooperation in eye health and aims to enhance the quality of eye health services through ongoing international collaboration [2]

Core Viewpoint - The company, Chaoyue Ophthalmology (02219.HK), announced a share buyback of 120,000 shares at a cost of HKD 310,000 on November 26 [1] Group 1 - The total expenditure for the share buyback was HKD 310,000 [1] - The number of shares repurchased was 120,000 [1]

Group 1 - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan [1] - The company will spend HKD 308,400 to repurchase 120,000 shares [1] - The buyback is scheduled for November 26, 2025 [1]

Group 1 - The event "China-Europe Biopharmaceutical Industry Innovation Cooperation Matchmaking Conference - China-Italy Eye Health Innovation Cooperation Special Session" was held in Beijing, organized by NICTC and the Naples service office of Zhongguancun Enterprises in Italy, with participation from various eye care and technology institutions from China and Italy [2] - He Eye Hospital, a technology-driven listed company, aims to create a comprehensive ecosystem for eye health, focusing on global innovation and serving the Chinese public [2][3] - The collaboration with Italian partners will focus on key areas such as refractive cataract, myopia prevention in youth, and dry eye treatment, promoting the transformation of international innovative technologies into products and clinical applications [2][3] Group 2 - Adaptica's Professor Ksenija Ili introduced a new product developed in collaboration with He Eye Hospital, which will provide public eye health services to youth and underdeveloped regions through AI screening devices [3] - He Eye Hospital has been dedicated to eye health for 30 years, combining technological innovation with public service to create a new ecosystem for eye health, recognized for its sustainable and replicable "three-tier eye health service model" [3] - The successful hosting of the China-Italy Eye Health Innovation Cooperation Special Session marks an important step for He Eye Hospital in promoting international eye health cooperation and contributing to the "Healthy China" initiative [3]

"每一次为患者手术，都是一份信任的托付。突破400例，意味着我们肩上的责任更重一分。"刘云川表示，"真正 的精准医疗，不在于追求最高的手术量，而在于为每一双眼睛找到最理想的手术方案。我们的核心差异在于，始 终坚持以专家的深度思考驾驭前沿技术，将科技的确定性与我们经验的灵活性相结合，为患者铺就一条安心、清 晰的视觉之路。" 日前，国内屈光手术权威专家、济南爱尔眼科（300015）医院刘云川院长主导的新一代蔡司VISUMAX800机器人 全飞秒手术(SMILE pro)成功突破400例。 400例手术，是四百次精准的个性化定制。在刘云川看来，顶尖设备是基石，而专家的"精"与"验"才是实现卓越疗 效的核心。每一台SMILE pro手术的背后，都是她基于深厚理论功底与数十年近视手术临床经验所做的精准判 断：面对不同的角膜条件与用眼需求，刘云川团队在术前进行精细化数据解读，确保手术方案与每位患者的眼部 条件及生活品质追求完美契合。凭借对设备性能的极致理解与炉火纯青的操作，她将"10秒内完成切削"的技术参 数，升华为"稳、准、柔"的患者手术体验，帮助患者获得长期、稳定的视觉健康。 ...

Core Viewpoint - The company, Chaoyue Eye Care (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares at a total cost of HKD 307,800 [1] - The buyback price per share ranges from HKD 2.53 to HKD 2.58 [1]

Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 307,800 to repurchase 120,000 shares [1] - The buyback price per share ranges from HKD 2.53 to HKD 2.58 [1]

Core Viewpoint - The company, Chaoyue Ophthalmology (02219.HK), announced a share buyback on November 24, spending HKD 310,000 to repurchase 120,000 shares [1] Group 1 - The total expenditure for the share buyback was HKD 310,000 [1] - The number of shares repurchased in this transaction was 120,000 [1]

Core Insights - The establishment of the first "Difficult Lacrimal Disease Diagnosis and Treatment Center" by Aier Eye Hospital Group in Wuhan aims to provide specialized care for complex lacrimal diseases, leveraging multidisciplinary collaboration and precision treatment [1][2] - The center focuses on conditions such as lacrimal duct adhesion, chronic lacrimal duct rupture, and congenital absence of lacrimal ducts, addressing a significant healthcare need in Central China and nationwide [1] - Aier Eye Hospital plans to create a tiered diagnosis and treatment database for lacrimal diseases, standardizing treatment protocols and establishing a comprehensive service loop from diagnosis to rehabilitation [2] Summary by Sections Establishment and Purpose - Aier Eye Hospital Group has inaugurated its first center dedicated to difficult lacrimal diseases in Wuhan, which will serve as a model for future centers across the country [1] - The center aims to provide one-stop diagnostic and treatment services for patients suffering from complex lacrimal conditions [1] Medical Collaboration and Expertise - The center integrates experts from various fields, including lacrimal, nasal, and imaging specialties, to create a systematic multidisciplinary treatment approach [1] - The clinical challenges associated with complex lacrimal diseases often stem from trauma, inflammation, congenital abnormalities, or previous surgical failures, leading to low success rates in conventional surgeries [1] Future Plans and Community Support - Aier Eye Hospital intends to establish additional centers across the country, contributing to a national network for specialized lacrimal disease treatment [2] - The organization is also collaborating with the Eye Care Charity Foundation to provide financial assistance of up to 3,000 yuan for eligible patients, alleviating their economic burden and promoting eye health [2]

Core Insights - The International Retina Summit 100 (IRS100·2025) was held in Changsha, China, focusing on the theme "Focusing on Clinical, Integrating Innovation, Building Brightness Together" [1][2] - The event featured over 300 ophthalmology experts discussing cutting-edge technologies and solutions for retinal diseases, emphasizing global collaboration and innovation in the field [2][4] Group 1: Event Overview - IRS100·2025 included various forums covering topics such as gene therapy, artificial intelligence, surgical robotics, and stem cell research, showcasing the latest advancements in retinal medicine [1][2] - The summit aimed to enhance academic exchanges and promote the efficient translation of scientific achievements into clinical applications [4][6] Group 2: Key Contributions and Research - Notable experts presented significant research findings, including the identification of new pathogenic genes for familial exudative vitreoretinopathy (FEVR) and advancements in the treatment of retinoblastoma [10][12] - The summit highlighted the importance of early intervention in diabetic retinopathy and the potential of innovative treatment methods to improve patient outcomes [16][17] Group 3: Future Directions - The event underscored the need for international cooperation and foundational research breakthroughs to elevate the standard of care for retinal diseases [8][19] - The commitment to integrating AI, gene therapy, and robotic surgery into clinical practice was emphasized as a strategy to enhance personalized and precise solutions for complex retinal conditions [19][20]